Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

N/ACompletedNCT01956799

Fondazione Italiana Sindromi Mielodisplastiche-ETS100 enrolled

Overview

The study aims to evaluate the molecular mechanism underlying the erythroid response observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Myelodysplasia Myelofibrosis Aplastic Anemia

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients aged 18 and older 2. Diagnosis of Myelodysplasia, myelofibrosis or aplastic anemia 3. transfusion-dependent anemia undergoing chelation therapy with deferasirox or deferoxamine Exclusion Criteria: * none

Locations (20)

Ematologia, AO SS. Antonio e Biagio

Alessandria, AL, Italy

Clinica di Ematologia, AOU Ospedale di Torrette

Outcomes

Primary Outcomes

To assess the molecular mechanism underlying the erythroid response

The primary outcome is to evaluate the molecular mechanism underlying the erythroid response (hemogoblin increase and reduction or elimination of trasfusion dependence) observed in some patients with myelodysplasia, myelofibrosis and aplastic anemia treated with Deferasirox or Deferoxamina

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.